| abstract |
The compound shown below (compound I) and a process for preparing this compound are disclosed wherein: R is hydrogen, lower alkyl, lower alkoxy, hydrogen or trifluoromethyl R1 is hydrogen or halogen or; R and R1 may be together with the ring carbon atoms to which they are attached -CH=CH-CH=CH-; R2 and R2' are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano or; R2 and R2' may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R3 and R3' are independently from each other hydrogen, lower alkyl or cycloalkyl; R4 and R4' are independently from each other -(CH2)mOR6 or lower alkyl; or R4 and R4' form together with the N-atom to which they are attached a cyclic tertiary amine of the group R5 is hydrogen, hydroxy, lower alkyl, -lower alkoxy, -(CH2)mOH, -COOR3, -CON(R3)2, -N(R3)CO-lower alkyl; or -C(O)R3; R6 is hydrogen, lower alkyl or phenyl: X is -C(O)N(R6)-, -N(R6)C(O)-, -(CH2)mO- or -O(CH2)m- n is 0, 1, 2, 3, or 4; and m is 1, 2, or 3; The use of these compounds in the treatment of diseases related to NK-1 receptor antagonists is also disclosed. |